Zimmer Biomet (NYSE:ZBH) Hits New 1-Year Low – What’s Next?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reached a new 52-week low during trading on Monday . The company traded as low as $79.60 and last traded at $79.1940, with a volume of 672006 shares traded. The stock had previously closed at $82.33.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of research reports. Leerink Partners initiated coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They issued a “hold” rating and a $101.00 target price on the stock. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Stifel Nicolaus cut their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Finally, William Blair assumed coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $102.80.

Zimmer Biomet Price Performance

The stock’s fifty day moving average price is $90.48 and its 200-day moving average price is $91.86. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm has a market cap of $15.99 billion, a price-to-earnings ratio of 21.47, a price-to-earnings-growth ratio of 1.93 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the previous year, the business earned $1.81 earnings per share. The firm’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date was Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.2%. Zimmer Biomet’s payout ratio is currently 24.94%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Dodge & Cox increased its stake in Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock valued at $2,113,736,000 after buying an additional 290,676 shares during the period. Vanguard Group Inc. increased its stake in Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock valued at $2,111,658,000 after buying an additional 192,517 shares during the period. State Street Corp increased its stake in Zimmer Biomet by 2.3% in the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock valued at $795,814,000 after buying an additional 195,214 shares during the period. Capital International Investors increased its stake in Zimmer Biomet by 11.5% in the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after buying an additional 778,467 shares during the period. Finally, Franklin Resources Inc. increased its stake in Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after buying an additional 2,017,857 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.